Loading quotes...

Forecast

The analysts' average price target is €4.92 (+116.74%). The median is €4.92 (+116.74%).

Buy	3
Hold	1
Sell	0

News Go to news feed

Leap Therapeutics secures $58.9 million from Winklevoss Capital — shares surge

Leap Therapeutics reports a private placement led by Winklevoss Capital with commitments of about $58.9 million. The deal entails the sale of roughly 95.8 million common shares or pre-funded warrants, plus warrants for an additional 71.9 million shares, at $0.5335 per share. Winklevoss Capital receives two board nominations including the chair; the capital is to be used in part to further develop the FL-501 and sirexatamab therapy programs. The stock rose intraday by 82.2%; the transaction is expected to close on October 8. » More on de.investing.com

Financials

In the last quarter, Leap Therapeutics Aktie had revenue of €0 and net profit of €67.61M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	67.61M	578.84%
EBITDA	-4.11M	70.89%

Fundamentals

Metric	Value
Market capitalization	€28.48M
Number of shares	41.39M
52-week high/low	€3.20 - €0.20
Dividends	No
Beta	0.09
P/E ratio	5.05
PEG ratio	0.00
P/B ratio	3.77
P/S ratio	0.00

Company profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.